532. Recurrent C. difficile in Children: Not Easy to Cure
Session: Poster Abstract Session: Healthcare Epidemiology: Updates in C. difficile
Thursday, October 4, 2018
Room: S Poster Hall


Little is known about the clinical characteristics and appropriate treatment of children with repeated C. difficile infections (rCDI). Current IDSA treatment recommendations for rCDI include oral vancomycin (VAN) or metronidazole (MTZ) based on weak/low quality evidence.


We performed a retrospective chart review of children hospitalized at CHAM with rCDI from 9/2009 to 10/2017. This cohort was extracted using ICD 9 or 10 codes from the electronic health record. Subsequent full chart review was performed to identify patients with rCDI, which was defined as symptomatic diarrhea in the context of repeat positive C. difficile toxin assay and diarrhea. Recurrence (recr), relapse (rspd), and cure with relapse (CWR) were defined based on time to new CDI: >14-60, ≤365 and >365 days, respectively. Global cure (G/C) was defined as the absence of rCDI up to 4/2018. Symptoms severity was graded based on the presence of WBC >12 or <2 k/uL, elevated creatinine adjusted by age, and serum albumin <3 mg/dL. Fisher’s Exact, χ2, Mann-Whitney were used for analyses.


We identified 28 children with rCDI (12 male and 16 female) with an average age of 9 ± 6 yr. The 3 most common diseases associated with rCDI were (n, %): stem cell transplantation (8, 28.6%), malignancy (6, 21.4%), and IBD (5, 17.9%). After the 1st episode of rCDI, 53.5% (95% CI 34-72%) experienced recr, rspd or CWR with an average number of 1.27 ± 0.46 repeat CDI episodes.  The symptoms of rCDI were generally mild (n=24; 85.7%), while moderate (n=3; 10.7%), and severe disease (n=1; 3.6%) were significantly less common (p=<0.001). Antibiotics used to treat 1st episode of rCDI are shown in table 1. Average number of days from treatment of 1st to 2nd rCDI did not significantly differ among treatment courses (MTZ: 123d vs. VAN: 60d; p=0.91). The frequency of G/C increased with treatment course as follows:  1st (46.4%), 2nd (60%) and 3rd (83.3%) (χ2 for trend, p=0.09, table 1).


Multiple rCDI occurred in a significant proportion of children with relatively poor clinical response. MTZ was disproportionately used in the treatment of rCDI. Use of NTZ appears to be associated high rate of G/C though our numbers were very small. Additional multi-site study is indicated to determine the optimal treatment of children with rCDI.

Philip Lee, Pharm D.1,2, Olga Aroniadis, MD3, Sarah Noble, M4 Medical Student4, Fatimah Rimawi, M4 Medical Student4 and David Goldman, M.D1,5, (1)Division of Pediatric Infectious Disease, Children's Hospital at Montefiore, Bronx, NY, (2)Department of Pharmacy, Children's Hospital at Montefiore, Bronx, NY, (3)Division of Gastroenterology, Montefiore Medical Center, Bronx, NY, (4)Albert Einstein College of Medicine, Bronx, NY, (5)Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY


P. Lee, Astra Zenena: Consultant , Consulting fee .

O. Aroniadis, None

S. Noble, None

F. Rimawi, None

D. Goldman, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.